These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10769781)

  • 1. Solubility and dissolution properties of generic rifampicin raw materials.
    Henwood SQ; de Villiers MM; Liebenberg W; Lötter AP
    Drug Dev Ind Pharm; 2000 Apr; 26(4):403-8. PubMed ID: 10769781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates.
    Henwood SQ; Liebenberg W; Tiedt LR; Lötter AP; de Villiers MM
    Drug Dev Ind Pharm; 2001 Nov; 27(10):1017-30. PubMed ID: 11794804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of amorphous content on dissolution characteristics of rifampicin.
    Panchagnula R; Bhardwaj V
    Drug Dev Ind Pharm; 2008 Jun; 34(6):642-9. PubMed ID: 18568915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance.
    Agrawal S; Ashokraj Y; Bharatam PV; Pillai O; Panchagnula R
    Eur J Pharm Sci; 2004 Jun; 22(2-3):127-44. PubMed ID: 15158898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation.
    Singh C; Bhatt TD; Gill MS; Suresh S
    Int J Pharm; 2014 Jan; 460(1-2):220-7. PubMed ID: 24188983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of zopiclone crystal forms found among generic raw materials.
    Terblanche RJ; Liebenberg W; de Villiers MM; Lötter AP
    Drug Dev Ind Pharm; 2000 May; 26(5):531-7. PubMed ID: 10789065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis.
    Melo KJC; Henostroza MAB; Löbenberg R; Bou-Chacra NA
    Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110895. PubMed ID: 32409052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin.
    Ammar HO; Khalil RM
    Pharmazie; 1996 Mar; 51(3):165-8. PubMed ID: 8900866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of polymorphism on powder compaction and dissolution properties of chemically equivalent oxytetracycline hydrochloride powders.
    Liebenberg W; de Villiers MM; Wurster DE; Swanepoel E; Dekker TG; Lötter AP
    Drug Dev Ind Pharm; 1999 Sep; 25(9):1027-33. PubMed ID: 10518242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers.
    Kumar PV; Asthana A; Dutta T; Jain NK
    J Drug Target; 2006 Sep; 14(8):546-56. PubMed ID: 17050121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
    Singh H; Jindal S; Singh M; Sharma G; Kaur IP
    Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.
    Panchagnula R; Agrawal S
    Int J Pharm; 2004 Mar; 271(1-2):1-4. PubMed ID: 15129967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Situ Monitoring and Modeling of the Solution-Mediated Polymorphic Transformation of Rifampicin: From Form II to Form I.
    Guo N; Hou B; Wang N; Xiao Y; Huang J; Guo Y; Zong S; Hao H
    J Pharm Sci; 2018 Jan; 107(1):344-352. PubMed ID: 29031974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
    Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
    Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.
    Becker C; Dressman JB; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
    J Pharm Sci; 2009 Jul; 98(7):2252-67. PubMed ID: 19160441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supercritical antisolvent co-precipitation of rifampicin and ethyl cellulose.
    Djerafi R; Swanepoel A; Crampon C; Kalombo L; Labuschagne P; Badens E; Masmoudi Y
    Eur J Pharm Sci; 2017 May; 102():161-171. PubMed ID: 28302396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy.
    Pund S; Joshi A; Vasu K; Nivsarkar M; Shishoo C
    Int J Pharm; 2011 Jun; 411(1-2):106-12. PubMed ID: 21458549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of sustained release rifampicin microparticles for inhalation.
    Son YJ; McConville JT
    J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.